Cargando…

Microvascular Dysfunction in Hypertrophic Cardiomyopathy

Myocardial ischemia is an established pathophysiological feature of hypertrophic cardiomyopathy (HCM) that impacts various clinical features, including heart failure (HF) and sudden cardiac death (SCD). The major determinant of myocardial ischemia in HCM is coronary microvascular dysfunction (CMD) i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pelliccia, Francesco, Cecchi, Franco, Olivotto, Iacopo, Camici, Paolo G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658510/ https://www.ncbi.nlm.nih.gov/pubmed/36362787 http://dx.doi.org/10.3390/jcm11216560

Ejemplares similares

Hypertrophic cardiomyopathy: The need for randomized trials
por: Olivotto, Iacopo, et al.
Publicado: (2013)

Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy
por: Bernardini, Andrea, et al.
Publicado: (2023)

Stage-specific therapy for hypertrophic cardiomyopathy
por: Argirò, Alessia, et al.
Publicado: (2023)

Septal Ablation Versus Surgical Myomectomy for Hypertrophic Obstructive Cardiomyopathy
por: Pelliccia, F., et al.
Publicado: (2021)

Clinical and molecular classification of cardiomyopathies
por: Cecchi, Franco, et al.
Publicado: (2012)

Plasmatic and myocardial microRNA profiles in patients with Hypertrophic Cardiomyopathy
por: Lombardi, Maria, et al.
Publicado: (2021)

Mitochondrial Energetics and Ca(2+)-Activated ATPase in Obstructive Hypertrophic Cardiomyopathy
por: Lombardi, Maria, et al.
Publicado: (2020)

Emerging Medical Treatment for Hypertrophic Cardiomyopathy
por: Argirò, Alessia, et al.
Publicado: (2021)

Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment
por: Losi, Maria-Angela, et al.
Publicado: (2010)

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside
por: Palandri, Chiara, et al.
Publicado: (2022)

Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different?
por: Jaafar, Nawel, et al.
Publicado: (2015)

Hypertrophic Cardiomyopathy—Current Challenges and Future Perspectives
por: Monda, Emanuele, et al.
Publicado: (2023)

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing?
por: Mazzarotto, Francesco, et al.
Publicado: (2020)

Myosins and MyomiR Network in Patients with Obstructive Hypertrophic Cardiomyopathy
por: Foglieni, Chiara, et al.
Publicado: (2022)

Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy
por: El-Hamamsy, Ismail, et al.
Publicado: (2012)

RNA‐seq profiling reveals different pathways between remodeled vessels and myocardium in hypertrophic cardiomyopathy
por: Pisano, Annalinda, et al.
Publicado: (2022)

Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy
por: Maurizi, Niccolò, et al.
Publicado: (2023)

MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy
por: Shridhar, Puneeth, et al.
Publicado: (2023)

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter
por: Masri, Ahmad, et al.
Publicado: (2022)

Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations
por: Coppini, Raffaele, et al.
Publicado: (2014)

Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy
por: Finocchiaro, Gherardo, et al.
Publicado: (2017)

Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions
por: Girolami, Francesca, et al.
Publicado: (2023)

INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan)
por: Olivotto, Iacopo, et al.
Publicado: (2015)

Coronary microvascular disease in hypertrophic and infiltrative cardiomyopathies
por: Giannopoulos, Andreas A., et al.
Publicado: (2022)

Cardiovascular magnetic resonance detects microvascular dysfunction in a mouse model of hypertrophic cardiomyopathy
por: Ku, Min-Chi, et al.
Publicado: (2021)

Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry
por: Marstrand, Peter, et al.
Publicado: (2020)

Report on the 2nd Florence International Symposium on Advances in Cardiomyopathies: 9th meeting of the European Myocardial and Pericardial Diseases WG of the ESC
por: Cecchi, Franco, et al.
Publicado: (2013)

Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry
por: Canepa, Marco, et al.
Publicado: (2020)

Pathogenic Mechanisms of Hypertrophic Cardiomyopathy beyond Sarcomere Dysfunction
por: Chou, Chun, et al.
Publicado: (2021)

Refractory microvascular angina in hypertrophic cardiomyopathy: a novel therapy?
por: Cheng, Kevin, et al.
Publicado: (2022)

Revisiting Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Current Practice and Novel Perspectives
por: Ottaviani, Andrea, et al.
Publicado: (2023)

Microvascular Dysfunction Is Associated With Impaired Myocardial Work in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy: A Multimodality Study
por: Garcia Brás, Pedro, et al.
Publicado: (2023)

Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective
por: Gragnano, Felice, et al.
Publicado: (2023)

Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy
por: Velicki, Lazar, et al.
Publicado: (2020)

Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
por: Ho, Carolyn Y., et al.
Publicado: (2018)

Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center
por: Mazzarotto, Francesco, et al.
Publicado: (2018)

Cardiogenic Shock in Obstructive Hypertrophic Cardiomyopathy Plus Apical Ballooning: Management With VA-ECMO and Myectomy
por: Caniato, Flavia, et al.
Publicado: (2021)

Hypertrophic cardiomyopathy
por: Antunes, Murillo de Oliveira, et al.
Publicado: (2020)

Microstructural and Microvascular Phenotype of Sarcomere Mutation Carriers and Overt Hypertrophic Cardiomyopathy
por: Joy, George, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jn5vff0665511op2ju91erndqv